搞笑了！金城医药实控人带头操纵自家股票，动用100多个账户，成交额超20亿，结果倒亏700多万

Core Viewpoint - Jincheng Pharmaceutical's actual controller and two accomplices engaged in stock manipulation over two and a half years, resulting in significant financial losses and regulatory penalties, including a four-year market ban for the chairman [2][3][4]. Group 1: Regulatory Actions - On August 15, 2024, Jincheng Pharmaceutical announced that its actual controller, Zhao Yeqing, received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into alleged market manipulation [2][4]. - On March 12, 2025, Zhao Yeqing and two others were notified of a proposed fine totaling 46.3174 million yuan, with Zhao personally liable for 23.1587 million yuan, alongside a four-year market ban [3][4][6]. - After a lengthy process, the final administrative penalty was issued on December 10, 2025, confirming the fines and market bans [4][6]. Group 2: Manipulation Details - From August 18, 2017, to February 10, 2020, Zhao Yeqing, Wang Zhen, and Liu Feng manipulated Jincheng Pharmaceutical's stock using 104 accounts, with Zhao as the decision-maker [5][17]. - The manipulation involved concentrated buying and selling, with a total trading volume of 21.34 billion yuan in purchases and 18.7 billion yuan in sales over 595 trading days [6][18]. - Despite the manipulation, the group incurred a loss of 7.392 million yuan during this period, highlighting the ineffective nature of their actions [7][19]. Group 3: Company Performance - Jincheng Pharmaceutical, established in 2004 and listed on the Shenzhen Stock Exchange in 2011, has struggled with stagnant revenues around 3 billion yuan and fluctuating net profits [9][21]. - In recent years, the company reported a significant decline in net profit, with a drop of over 80% in non-recurring net profit in the first three quarters of the current year, amounting to just over 20 million yuan [9][21]. - As of December 11, 2023, the company's market capitalization was approximately 5.8 billion yuan [10][22].